NFKB1 and cancer: In that PPARγ agonists inhibit both NF-κB- and Stat3-mediated transactivation of target genes and both of these transcription factors play a prominent role in cancer progression (see Section 2.8 and references therein), it is a likely extension to consider a role for PPARγ agonists to target CSCs.